Latest Trends of Leukemia Therapeutics Market 2019
Leukemia Therapeutics Market by Type (CLL, ALL, CML, AML), Treatment Type (Chemotherapy & Targeted Drugs by (CLL, ALL, CML, AML)), Mode of Administration (Oral, Injectable), Molecule Type (Small Molecules, Biologics), Gender, and Region
(EMAILWIRE.COM, May 31, 2019 ) he leukemia therapeutics market is projected to reach USD 17.1 billion by 2024 from USD 12.3 billion in 2019, at a CAGR of 6.8% during the forecast period
Market growth is largely driven by the rising prevalence of acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML) and increasing approvals of novel & innovative drugs and immunotherapies.
Download FREE Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=223
Key Market Players
The major players in this market are AbbVie (US), Bristol-Myers Squibb (US), Novartis (Switzerland, F. Hoffmann-La Roche (Switzerland), Pfizer (US), Sanofi (France), Amgen (US), Gilead Sciences (US), Takeda Pharmaceutical (Japan), and Celgene (US). Product approvals are a key strategy adopted by key players in order to enhance their dominance in this market.
Novartis is leading the global leukemia therapeutics market, owing to its strong sales channel and innovative therapies. The company invested ~17.5% of its revenue for its R&D activities. In May 2018, Novartis launched its CAR-T cell therapy for the second indication—treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma. With the innovative launch of Kymriah, Novartis is now a pioneer of leukemia immunotherapies.
Request for Sample @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=223
There has been a tremendous increase in cell-based research activities over the past decade. Increasing research in the field of regenerative medicine for the treatment of leukemia and growing awareness on personalized medicine have also resulted in the growth of this market. In addition to it, the growth in this market is driven by the high prevalence and incidence of leukemia and the rising geriatric population. According to the Leukemia & Lymphoma Society, an estimated 381,774 people are living with or in remission from leukemia in the US.
The Canadian government is taking various initiatives to support leukemia research and develop novel immunotherapies. For instance, in January 2016, the Canadian government announced the provision of USD 20 million to the Centre for Commercialization of Regenerative Medicine (CCRM) to help establish a stem cell therapy development facility in Toronto (Canada).
Market growth is largely driven by the rising prevalence of acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML) and increasing approvals of novel & innovative drugs and immunotherapies.
Download FREE Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=223
Key Market Players
The major players in this market are AbbVie (US), Bristol-Myers Squibb (US), Novartis (Switzerland, F. Hoffmann-La Roche (Switzerland), Pfizer (US), Sanofi (France), Amgen (US), Gilead Sciences (US), Takeda Pharmaceutical (Japan), and Celgene (US). Product approvals are a key strategy adopted by key players in order to enhance their dominance in this market.
Novartis is leading the global leukemia therapeutics market, owing to its strong sales channel and innovative therapies. The company invested ~17.5% of its revenue for its R&D activities. In May 2018, Novartis launched its CAR-T cell therapy for the second indication—treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma. With the innovative launch of Kymriah, Novartis is now a pioneer of leukemia immunotherapies.
Request for Sample @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=223
There has been a tremendous increase in cell-based research activities over the past decade. Increasing research in the field of regenerative medicine for the treatment of leukemia and growing awareness on personalized medicine have also resulted in the growth of this market. In addition to it, the growth in this market is driven by the high prevalence and incidence of leukemia and the rising geriatric population. According to the Leukemia & Lymphoma Society, an estimated 381,774 people are living with or in remission from leukemia in the US.
The Canadian government is taking various initiatives to support leukemia research and develop novel immunotherapies. For instance, in January 2016, the Canadian government announced the provision of USD 20 million to the Centre for Commercialization of Regenerative Medicine (CCRM) to help establish a stem cell therapy development facility in Toronto (Canada).
Contact Information:
MarketsandMarkets™
Mr. Shelly Singh
Tel: 1-888-600-6441
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
MarketsandMarkets™
Mr. Shelly Singh
Tel: 1-888-600-6441
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results